Our
Ikigai
Our reason for being
what we love
what the
world needs
what is
economically
sustainable
what we
are good at
Ikigai compounds two Japanese words: iki meaning «life» and gai meaning «result». Hence, Ikigai is a Japanese concept that means «a reason for being». The word refers to having a meaningful direction: our purpose in life.
Having a clear and defined ikigai gives satisfaction, passion, happiness, and meaning to life. At Towa our Ikigai is clear…
At Towa International, we contribute to people’s health. We are dedicated to genuine smiles
We want to be an active player in the national sustainability health systems and provide high-quality and valued medicines through our R&D center, as well as the international presence and strategic alliances, to patients around the world.
Our
commitments
Our
people
We have a shared vision
As part of Towa, we are health ambassadors, starting with ourselves and our surroundings. #WeAreCommittedToHealth
We are more than 900 professionals across 4 countries: Spain, Italy, Portugal, and the United States of America.
Towa’s human team is behind the success of our high-quality products and services.
They are our key element
Real people who internalize the corporate philosophy as part of their DNA and work every day to contribute directly to the purpose of our company.
We want to be recognized for caring for people’s health, starting with our own, and for flexibility.
We want to be the company where people decide to stay because of our purpose and our well-being.
We have two axes of the value proposition to our employees and part of the culture that as Towa we want to promote.
Health__________Flexibility
We are going to work intensely to advance with measures in both areas so that all of us can balance our personal lives with the responsibilities of our work. This will improve the efficiency of our organization and our health and well-being.
From Towa
to the World
Our Journey begins in 1951
Towa Pharmaceutical was founded in Osaka, Japan as a wholesale and brokerage of pharmaceutical raw materials.
Towa Group contributes to people’s health by creating superior products and services.
Through our corporate activities, we aim to be a company that is valued and needed by patients, medical professionals, local communities, and others.
In 2020 Towa became international by adding the Pensa Pharma business, a well-established patent medicine platform with a commercial presence in the US and the EU and R&D and manufacturing capabilities.
Through this internationalization milestone, Towa International headquarters were established in Barcelona, Spain.
At Towa International, we work to research, develop and market generic and value-added medicines (VAM) that contribute to improving the health of patients. In turn, they allow greater availability and better management of treatments for health professionals and support the sustainability of health systems in more than 30 countries in which we operate.
#FromTowaToTheWorld
Our story together
TOWA
PHARMACEUTICAL
TOWA
INTERNATIONAL
1951
Towa Pharmaceutical was founded.
1989
Pensa originates from PPI expertise and a non-infringement formulation of Omeprazole
1992
Contruction of Martorelles (Barcelona) manufacturing and R&D facilities
1996
Mr. Itsuro Yoshida became the president
1998
Creation of B2B business
1998
Osaka Research Center and Osaka Distribution Center are constructed at Ichiban-cho, Kadoma, Osaka
1999
Launch of Omeprazole
2004
Towa was listed on stock exchange
2006
Pensa Pharma Foundation
2007
Start of the internationalisation phase. Expanded Pensa into Italy with the purchase of 20 additional products.
2008
Built pilot plant and expanded R&D capabilities. Entered Portugal through the acquisition of toLife, adding 30 additional products to Pensa’s portfolio
2009
Entered U.S.A with acquisition of Breckenridge. Entered Sweeden
2010
Towa purchases Daichi Kasei Co., Ltd., and makes it subsidiary
2012
Entered Germany
2016
Established Greencaps Pharmaceutical Co., Ltd.
2020
Foundation of Towa Pharma International Holding
2020
Internationalisation
2021
Expansion manufacturing facilities
2021
Towa purchases Protosera Inc. and makes it subsidiary
2022
Internalization process. Entering South America and Middle East though licenses
2022
Towa purchases Sunsho Pharmaceutical Co., Ltd. and makes it subsidiary
Towa
Pharmaceutical
Towa Presence in Japan
Major Group
Companies
Greencaps Pharmaceutical.Co., Ltd.
Producing soft capsules for pharmaceutical products. Headquarters: Fujinomiya, Shizuoka, Japan.
Sunsho Pharmaceutical Co., Ltd.
Manufacturing and selling of ethical and OTC drugs. Capsules technology. Headquarters: Fuji, Shizuoka, Japan
J-DOLPH Pharmaceutical Co., Ltd.
Manufacturing and selling of ethical drugs. Headquarters: Koka, Shiga, Japan.
Daichi kasei, Co., Ltd.
R&D and manufacturing of APIs and intermediates. Headquarters: Fukusaki, Kanzaki, Hyogo, Japan.
Other health
services companies
T Square Solutions Co., Ltd.
Providing healthcare-related IT services. Headquarters: Settu, Osaka, Japan
Protosera Inc.
Disease risk testing service business and research and development of diagnostic drugs. Headquarters: Osaka, Osaka
We ensure to cover all the phases
of our value chain in our products
Active Pharmaceutical Ingredients (APIs)
Research and Development of Finished Dosage Forms (FDFs)
Regulatory Affairs and Quality Control
Manufacturing and Stable product supply
Marketing and distribution
Towa Pharmaceutical
In numbers
0st
generic medicines company ranking in Japan
+0B€
in sales
+0M€
R&D investment
+0
medicinal effect and mechanism
+0
employees
+0
products
+0B
tablets per year
0
Research centers
0
Manufacturing plant
Entering new
health-related business
As one of our challenges, we aim for creating a future that provides full coverage of medical expenses to care for pre-symptomatic disease and prevention for society with a long and healthy life expectancy.
In line with our vision of contributing to people’s health, we will work to create new health-related businesses that are suited to the new medical system, while acquiring new techniques and integrating them with completely new knowledge and technologies.
Specifically, we will help build an infrastructure to create ideal local communities, and contribute to extending healthy life expectancy by providing necessary health promotion services to people in need of them.
Among our key measures, we will be launching testing services for determining disease risks, expanding the KENTO Healthcare Science Center, which opened in 2019 to conduct joint research with the National Cerebral and Cardiovascular Center to extend healthy life expectancy, and collecting/ utilizing information obtained from testing to provide appropriate health-related services.
Key measures
-
Building a foundation for extending healthy life expectancy by utilizing key data
-
Contributing to the Comprehensive Community Care System
-
Further enhancing the lineup of products and services to maintain and improve health
-
Entering disease risk testing service business
-
Creating synergies with existing businesses
Ethics &
Compliance
At Towa, we promote a culture of ethics and integrity, based on our Ethics Code, which is a compass to guide our business
decisions with integrity. Our Ethics Code is both an internal guideline for the employees and an external statement of corporate
values and commitments that also must be observed by our stakeholders (suppliers, customers or agents operating on our behalf).
We are committed to do business only with 3rd parties that operate in an ethical manner consistent with our own principles.
We recognize the importance of an open communication when it comes to addressing concerns related to the misconduct or
violation of our ethical principals.